<MedlineCitation Status="Completed">
<MedlineID>10011663</MedlineID>
<PMID>369646</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0007-1447</ISSN>
<JournalIssue>
<Volume>1</Volume>
<Issue>6157</Issue>
<PubDate>
<Year>1979</Year>
<Month>Jan</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus.</ArticleTitle>
<Pagination>
<MedlinePgn>159-61</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The effects on diabetic control of the relative cardioselective beta-blocker metoprolol and the non-selective drug propranolol were compared in 20 hypertensive diabetic patients receiving diet alone or diet and oral hypoglycaemic agents. Each drug was given for one month in a double-blind, cross-over study. Fasting, noon, and mid-afternoon blood sugar concentrations rose by 1.0-1.5 mmol/l (18-27 mg/100 ml). The rise with propranolol was not significantly greater than with metoprolol. In a few patients the rise was clinically important. The small overall change observed in diabetic control should not deter the use of beta-blockers in non-insulin-dependent diabetics, provided control is carefully monitored at the onset of treatment.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Wright</LastName>
<ForeName>A D</ForeName>
<Initials>AD</Initials>
</Author>
<Author>
<LastName>Barber</LastName>
<ForeName>S G</ForeName>
<Initials>SG</Initials>
</Author>
<Author>
<LastName>Kendall</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author>
<LastName>Poole</LastName>
<ForeName>P H</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Br Med J</MedlineTA>
<NlmUniqueID>0372673</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Propanolamines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>37350-58-6</RegistryNumber>
<NameOfSubstance>Metoprolol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>525-66-6</RegistryNumber>
<NameOfSubstance>Propranolol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Blood Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Clinical Trials</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Comparative Study</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Diabetes Mellitus</DescriptorName>
<QualifierName MajorTopicYN="Y">blood</QualifierName>
<QualifierName>complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hypertension</DescriptorName>
<QualifierName>complications</QualifierName>
<QualifierName>drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Metoprolol</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Propanolamines</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Propranolol</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
